Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys completes first dosing in Phase I arthritis trial
Six healthy volunteers in the first dosing group have been enrolled and received MOR103 injections, while three volunteers received placebo. The safety review of the medical data from
Six healthy volunteers in the first dosing group have been enrolled and received MOR103 injections, while three volunteers received placebo. The safety review of the medical data from
These claims broadly cover URG101 and its use in the treatment of painful bladder syndrome (PBS) by administering a glycosaminoglycan (such as heparin) and a local anesthetic. Urigen
The formal marketing authorization by the European Commission is expected within the next few weeks. Oracea shall be the first drug marketed by MediGene itself. The recommendation for
Based on discussions held during the meeting and prior written communications between Duska and the FDA, the company believes that the FDA would consider a new drug application
Dr Hagey will be responsible for all aspects of pre-clinical and clinical development for Hana’s portfolio of cancer therapeutic and supportive care candidates, reporting to Steven Deitcher, Hana’s
Sartorius Stedim Biotech will offer the pH measurement option in its single-use Fluid Management Technology portfolio designed for the biopharmaceutical industry. The single-use pH sensor offers a wide
Most recently, Mr Fender served as vice president and general manager for Osiris Therapeutics, a stem cell therapeutic company focused on developing and marketing products to treat medical
Under the terms of the agreement, InSite grants exclusive rights to Biem to commercialize AzaSite for ocular bacterial infection in Turkey. An option to distribute to Biem’s export
Under the terms of the agreement, North Park is responsible for worldwide development and commercialization of products containing fluridil for all indications. North Park also acquired an option
The study is a multi-centre, randomized, double-blind and placebo-controlled study planned to include up to 420 patients. The patients are randomized to receive daily doses of either 45mg